Combination Drugs Work Against Virus
The study found that in patients at high risk, a combination of the oral antiviral drugs nirmatrelvir and ritonavir (Paxlovid), resulted in nearly a 90% reduction in hospitalization or death. This clinical trial led to the authorization of the combination drug therapy (Paxlovid) by the FDA.
Access to the full text article can be found here
Read FDA News Release on Paxlovid Authorization here
Read more LDA Articles on COVID treatment here